NSH 1329 A Phase Ib Open-label Study to Evaluate the Safety and Anti-cancer activity of Loncastuximab Tesirine in Combination with Other Anti-Cancer Therapies in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (LOTIS 7), NCT04970901

PI: Melhem Solh

Inclusion Criteria:

• Relapsed/Refractory DLBCL, HGBCL, transformed FL

• Only 1-2 prior lines of therapy allowed

• Prior CAR-T allowed but must be >100 days out

• ECOG 0-2

Exclusion Criteria:

• Primary refractory to CAR-T (progressive or persistent disease within 30 days)